News

GlaxoSmithKline announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP), and for Xyzal (levocetirizine dihydrochloride), the first...

Health Canada, the Canadian health authority, has approved PRADAX™ (dabigatran etexilate), 1 Boehringer Ingelheim’s novel, oral direct thrombin inhibitor 2 for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate,...

Tengion, Inc., a leader in regenerative medicine, announced that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit(TM) in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder...

AstraZeneca announced that it has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with placebo in adult patients with severe sepsis and/or septic shock receiving best supportive care. ...

Cipla, among the world's leading generic pharmaceutical companies has introduced Pirfenidone in India; under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5...

Sandoz anounced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US. Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe...

Sanofi-aventis announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientificex change between Harvard University and sanofi-aventis. The...